Zhuang Xiaomei, Lu Chuang
State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Department of DMPK, Biogen, Inc., Cambridge, MA 02142, USA.
Acta Pharm Sin B. 2016 Sep;6(5):430-440. doi: 10.1016/j.apsb.2016.04.004. Epub 2016 Jun 23.
Physiologically based pharmacokinetic (PBPK) modeling and simulation can be used to predict the pharmacokinetic behavior of drugs in humans using preclinical data. It can also explore the effects of various physiologic parameters such as age, ethnicity, or disease status on human pharmacokinetics, as well as guide dose and dose regiment selection and aid drug-drug interaction risk assessment. PBPK modeling has developed rapidly in the last decade within both the field of academia and the pharmaceutical industry, and has become an integral tool in drug discovery and development. In this mini-review, the concept and methodology of PBPK modeling are briefly introduced. Several case studies were discussed on how PBPK modeling and simulation can be utilized through various stages of drug discovery and development. These case studies are from our own work and the literature for better understanding of the absorption, distribution, metabolism and excretion (ADME) of a drug candidate, and the applications to increase efficiency, reduce the need for animal studies, and perhaps to replace clinical trials. The regulatory acceptance and industrial practices around PBPK modeling and simulation is also discussed.
基于生理的药代动力学(PBPK)建模与模拟可利用临床前数据预测药物在人体中的药代动力学行为。它还能探究各种生理参数(如年龄、种族或疾病状态)对人体药代动力学的影响,以及指导剂量和给药方案的选择,并辅助药物相互作用风险评估。在过去十年中,PBPK建模在学术界和制药行业都发展迅速,已成为药物研发中不可或缺的工具。在本综述中,简要介绍了PBPK建模的概念和方法。讨论了几个案例研究,阐述了如何在药物研发的各个阶段利用PBPK建模与模拟。这些案例研究来自我们自己的工作及文献,以便更好地理解候选药物的吸收、分布、代谢和排泄(ADME)情况,以及在提高效率、减少动物研究需求甚至可能替代临床试验方面的应用。还讨论了围绕PBPK建模与模拟的监管认可和行业实践。